Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography

被引：35

作者：

Martin, N

Catalin, J

Blachon, MF

Durand, A

机构：

[1] Fac Pharm Marseille, Lab Toxicocinet & Pharmacocinet, F-13385 Marseille 5, France

[2] CHU Timone, Lab Pharmacocinet & Toxicocinet, F-13385 Marseille, France

来源：

JOURNAL OF CHROMATOGRAPHY B | 1998年 / 709卷 / 02期

关键词：

paclitaxel; Taxol;

D O I：

10.1016/S0378-4347(98)00060-7

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

A new, rapid and sensitive high-performance liquid chromatographic method for the analysis of paclitaxel (Taxol) in human plasma and urine was developed and validated. After addition of an internal standard, paclitaxel was extracted from plasma or urine by a liquid-liquid extraction using diethyl ether. Extraction efficiency averaged 90%. Chromatography was performed isocratically on a reversed-phase column monitored at 227 nm. Retention times were 7.7 and 6.7 min for paclitaxel and docetaxel, respectively, and the assay was linear in the range 25-1000 ng/ml. The limits of quantification for paclitaxel were 25 and 40 ng/ml in plasma and urine, respectively. The assay was shown to be suitable for pharmacokinetic studies of children involved in a phase I clinical trial. (C) 1998 Elsevier Science B.V. All rights reserved.

引用

页码：281 / 288

页数：8

共 19 条

[1] PHARMACOKINETICS OF TAXOL AND DOXORUBICIN ADMINISTERED ALONE AND IN COMBINATION BY CONTINUOUS 72-HOUR INFUSION [J].

BERG, SL ;

COWAN, KH ;

BALIS, FM ;

FISHERMAN, JS ;

DENICOFF, AM ;

HILLIG, M ;

POPLACK, DG ;

OSHAUGHNESSY, JA .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (02) :143-145

[2]

CANO P, COMMUNICATION

[3]

DOZ F, 1998, UNPUB J CLIN ONCOL

[4] EUROPEAN-CANADIAN RANDOMIZED TRIAL OF PACLITAXEL IN RELAPSED OVARIAN-CANCER - HIGH-DOSE VERSUS LOW-DOSE AND LONG VERSUS SHORT INFUSION [J].

EISENHAUER, EA ;

HUININK, WWT ;

SWENERTON, KD ;

GIANNI, L ;

MYLES, J ;

VANDERBURG, MEL ;

KERR, I ;

VERMORKEN, JB ;

BUSER, K ;

COLOMBO, N ;

BACON, M ;

SANTABARBARA, P ;

ONETTO, N ;

WINOGRAD, B ;

CANETTA, R .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2654-2666

[5] NONLINEAR PHARMACOKINETICS AND METABOLISM OF PACLITAXEL AND ITS PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS IN HUMANS [J].

GIANNI, L ;

KEARNS, CM ;

GIANI, A ;

CAPRI, G ;

VIGANO, L ;

LOCATELLI, A ;

BONADONNA, G ;

EGORIN, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :180-190

[6]

GREM JL, 1987, CANCER TREAT REP, V71, P1179

[7] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE QUANTITATIVE-DETERMINATION OF PACLITAXEL (TAXOL) IN HUMAN URINE [J].

HUIZING, MT ;

ROSING, H ;

KOOPMAN, F ;

KEUNG, ACF ;

PINEDO, HM ;

BEIJNEN, JH .

JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 664 (02) :373-382

[8] PHARMACOKINETICS OF PACLITAXEL AND METABOLITES IN A RANDOMIZED COMPARATIVE-STUDY IN PLATINUM-PRETREATED OVARIAN-CANCER PATIENTS [J].

HUIZING, MT ;

KEUNG, ACF ;

ROSING, H ;

VANDERKUIJ, V ;

HUININK, WWT ;

MANDJES, IM ;

DUBBELMAN, AC ;

PINEDO, HM ;

BEIJNEN, JH .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2127-2135

[9] PHASE-I TRIAL OF PACLITAXEL IN CHILDREN WITH REFRACTORY SOLID TUMORS - A PEDIATRIC-ONCOLOGY-GROUP STUDY [J].

HURWITZ, CA ;

RELLING, MV ;

WEITMAN, SD ;

RAVINDRANATH, Y ;

VIETTI, TJ ;

STROTHER, DR ;

RAGAB, AH ;

PRATT, CB .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2324-2329

[10]

LONGNECKER SM, 1987, CANCER TREAT REP, V71, P53

← 1 2 →